Trendlyne Blog: , Latest on stock market and finance in India and the world.

19 Aug 2025

946.50

-0.07%

Alembic Pharma shares rise 2% on pulmonary hypertension drug approval

Business Standard

Alembic Pharma shares rose 2.3 per cent on Tuesday, after the company received US Food & Drug Administration (USFDA) final approval for its Abbreviated New Drug Application (ANDA) Macitentan Tablets

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Marksans Pharma Ltd.

18 Aug 2025

172.93

-0.73%

Marksans Pharma gains 3% on UK MHRA approval for subsidiary; details here

Business Standard

The upward movement in Marksans Pharma's share price came after the company announced that its wholly owned subsidiary, Relonchem in the UK, had received marketing authorisation for its products

Marksans Pharma Ltd. has lost -35.49% in the last 1 Year

Alembic Ltd.

18 Aug 2025

103.16

-0.80%

Alembic gets USFDA nod for generic drug for skin condition

Business Line

The company has received final approval from the US Food & Drug Administration for its abbreviated new drug application for Tretinoin Cream USP, the drug maker said in a statement

Alembic Ltd. has lost -33.65% in the last 1 Year

Alembic Pharmaceuticals Ltd.

18 Aug 2025

946.50

-0.07%

Alembic gets USFDA's approval for generic acne drug Tretinoin Cream

Business Standard

Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic medication to treat acne vulgaris in the US market. The company has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Tretinoin Cream USP (0.025 per cent), the drug maker said in a statement. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Retin-A Cream, 0.025 pr cent, of Bausch Health US, LLC, it added. Tretinoin cream is indicated for topical application in the treatment of acne vulgaris. According to IQVIA, Tretinoin cream USP, 0.025 per cent, has an estimated market size of USD 94 million for the twelve months ending June 2025. Shares of the company were trading 1.03 per cent up at Rs 968.10 apiece on BSE.

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.

Aurobindo Pharma Ltd.

17 Aug 2025

1094.40

-1.33%

Aurobindo Pharma expects China plant to break even at EBITDA level this year

Business Line

"This facility with an initial capacity of 2 bn units plus is ramping up as expected and will begin contributing to revenue in the coming quarters and is expected to break even at the EBITDA level by Q3 FY26"

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Aurobindo Pharma expects China plant to break even at Ebitda level in FY26

Business Standard | 17 Aug 2025

Glenmark Pharmaceuticals Ltd.

15 Aug 2025

2132.50

0.23%

Glenmark Pharmaceuticals Q1 PAT down 86% dragged by US litigation settlement provision

Business Line

Consolidated total revenue from operations in Q1FY26 stood at 3,264.44 crore as against 3,244.19 crore in the same period a year ago.

Glenmark Pharmaceuticals Ltd. has gained 30.06% in the last 3 Months

Glenmark Pharmaceuticals Q1 Results: Profit Plunges 86%

NDTV Profit | 14 Aug 2025 1 more

Strides Pharma Science Ltd.

14 Aug 2025

909.75

-0.14%

Strides towards Naya Bharat

Business Line

Strides Pharma Science Ltd. has gained 49.53% in the last 6 Months

Anthem Biosciences Ltd.

14 Aug 2025

833.50

1.53%

Recently listed biotech stock surges 44% against issue price; time to sell?

Business Standard

Shares of Anthem Biosciences surged 9 per cent to 820 on the BSE in Thursday's intra-day trade amid heavy volumes after reporting a strong earnings for the quarter ended June 2025.